Clinical Trials Sponsored by Atrium Health Levine Cancer Institute

Total 9002 results

National Cancer Institute (NCI)

Active, not recruiting

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

Brain Cancer | Brain Tumor | Neoplasm | Spine Cancer | Spine Tumor

United States
National Cancer Institute (NCI)

Enrolling by invitation

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Solid Tumors | Hematologic Malignancies | Pediatric Cancers

United States
National Cancer Institute (NCI)

Completed

FdCyd and THU for Advanced Solid Tumors

Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

Cancer | Death

United States
National Cancer Institute (NCI)

Completed

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

Neurofibroma | Neurofibromatosis Type 1

United States
National Cancer Institute (NCI)

Completed

BRCA Mutations in Latinas

Breast Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Completed

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NSCLC | Solid Tumors | Lymphomas | Granulosa Cell Ovarian Cancer | Metastatic Colon Carcinoma

United States
National Cancer Institute (NCI)

Completed

Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases

Cancer | Brain Metastasis

United States
National Cancer Institute (NCI)

Completed

A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners

Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

Adrenocortical Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Cause of Familial Testicular Cancer

Testicular Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Small Cell Lung Cancer | Extra-Pulmonary Small Cell Carcinomas

United States
National Cancer Institute (NCI)

Completed

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Refractory Soft Tissue Sarcomas

United States
National Cancer Institute (NCI)

Completed

Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)

Dyskeratosis Congenita | Telomere Biology Disorders

United States
National Cancer Institute (NCI)

Completed

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Burkitt Lymphoma | High-grade B-cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | T-cell/Histocyte-rich Large B-cell Lymphoma | Germinal Center B-cell Type (GCB)

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Vulvar, Vaginal, Penile, Rectal Cancer | HPV Positive Cancer

United States
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
National Cancer Institute (NCI)

Completed

LMB-2 to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Colorectal Tumors | Colorectal Carcinoma | Colorectal Cancer With Hepatic Metastases

United States
National Cancer Institute (NCI)

Suspended

Rare CNS Tumors Outcomes &Risk

Ependymoma | Medulloblastoma | PNET | High Grade Meningioma | Primary CNS Sarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Prostate Cancer | Prostate Neoplasms | Neoplasms, Prostatic

United States
National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
National Cancer Institute (NCI)

Completed

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Epithelioid Mesothelioma | Cholangiocarcinoma, Extrahepatic | Neoplasms With Mesothelin Expression | Adenocarcinoma, Pancreatic

United States
National Cancer Institute (NCI)

Active, not recruiting

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Pancreatic Cancer | Liver Metastasis

United States
National Cancer Institute (NCI)

Completed

Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity

Brain Tumors

United States
National Cancer Institute (NCI)

Completed

Collecting Solid Tumor Tissue to Identify New Treatments

Melanoma | Pancreatic Cancer | Gastrointestinal Cancer | Liver Cancer

United States
National Cancer Institute (NCI)

Completed

Blood Collection From People With Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Cancer of the Ovary

United States
National Cancer Institute (NCI)

Completed

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Burkitt Lymphoma | Plasmablastic Lymphoma | Diffuse Large B-cell Lymphoma, c-MYC Positive

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Completed

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

Lymphoma | Carcinoma

United States
National Cancer Institute (NCI)

Completed

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Terminated

Ruxolitinib for Adult T-Cell Leukemia

Leukemia, Adult T-Cell | T Cell Leukemia, Adult | T Cell Leukemia, HTLV I Associated

United States
National Cancer Institute (NCI)

Completed

High-Risk Breast Duct Epithelium

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer

Prostate Neoplasms | Prostate Specific Antigens

United States
National Cancer Institute (NCI)

Completed

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
National Cancer Institute (NCI)

Completed

M7824 in People With Recurrent Respiratory Papillomatosis

Human Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis

United States
National Cancer Institute (NCI)

Terminated

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

Thyroid Cancer | Low-risk Papillary Thyroid Cancer | Endocrine Malignancy

United States
National Cancer Institute (NCI)

Terminated

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

Leukemia, Lymphoblastic, Acute | ALL, Childhood

United States
National Cancer Institute (NCI)

Completed

Clinical and Laboratory Analysis of Familial Cancer

Cancer

United States
National Cancer Institute (NCI)

Terminated

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Neoplasms, Germ Cell and Embryonal | Lung Neoplasms | Esophageal Neoplasms | Thymus Neoplasms | Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States
National Cancer Institute (NCI)

Completed

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoplasms

United States

Clinical Trials Sponsored by Atrium Health Levine Cancer Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations